Article Text

Download PDFPDF

1205 Treatment of Lupus-prone BXSB Mice with a Modulatable CAR T cell System Targeting CD19
  1. Ivo Rimann1,
  2. Hua Huang1,
  3. Parker Mace1,
  4. Rosana Gonzalez-Quintial1,
  5. Eduardo Laborda1,
  6. Sophie Viaud2,
  7. Hannah Mora1,
  8. Argyrios N Theofilopoulos1,
  9. Travis S Young2 and
  10. Dwight H Kono1
  1. 1The Scripps Research Institute
  2. 2Calibr at Scripps Research


Chimeric antigen receptor (CAR) T cells directed against CD19 have demonstrated efficacy in treating active lupus in both human and mouse lupus. However, a significant limitation of this approach is immunodeficiency due to the long-term depletion of B cells. To address this issue, we studied the potential of a switchable CAR (sCAR) T cell system targeting CD19 to transiently eliminate B cells and provide therapeutic benefit with less immunosuppression. This approach consists of a CAR that, instead of targeting CD19 directly, binds to a soluble antiCD19 Fab switch with a short half-life, thereby allowing sCAR T cell killing only when the antiCD19 switch is present. Treatment of BXSB males with sCAR T plus continuous antiCD19 switch reduced B cell numbers, circulating immunoglobulins, autoantibodies, and nephritis. To document the efficacy of a shorter course of treatment, B6 mice were given three every other day doses of antiCD19 switch. There was depletion of virtually all CD19+ B cells and plasma cells from the bone marrow, spleen, and peritoneum, as well as most CD19- plasma cells in the bone marrow and spleen. When BXSB males with active disease were similarly treated, there was a transient elimination of B cells and disease remission associated with about a 2-month prolonged survival. To address whether recurrence could be prevented by repeated sCAR T+antiCD19 treatment, BXSB males with active lupus were given an additional two cycles of antiCD19 switch at 60 and 138 days. Circulating B cells, IgM and IgG, and anti-chromatin levels were reduced after each switch cycle and increased in the intervening periods. Notably, proteinuria did not recur, and there were no deaths beyond day 8 after the start of treatment compared with 100% mortality in the sCAR T+PBS controls. These studies inform on the potential effectiveness and limitations of therapeutic depletion of B cells in SLE and suggest a possible strategy for employing CAR T cells to minimize immunosuppression.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: .

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.